The Mental Health Clinician最新文献_第6页

Assessing the understandability, actionability, and quality of online resources for the self-management of bipolar disorder. 评估双相情感障碍自我管理在线资源的可理解性、可操作性和质量。

The Mental Health Clinician Pub Date : 2022-01-21 eCollection Date: 2022-01-01 DOI: 10.9740/mhc.2022.01.001

Nathan D Sutera, Courtney A Iuppa, Leigh Anne Nelson, Carrie R Kriz, Nicole A Gramlich, Shelby E Lang, Ellie S R Elliott, Roger W Sommi

{"title":"Assessing the understandability, actionability, and quality of online resources for the self-management of bipolar disorder.","authors":"Nathan D Sutera, Courtney A Iuppa, Leigh Anne Nelson, Carrie R Kriz, Nicole A Gramlich, Shelby E Lang, Ellie S R Elliott, Roger W Sommi","doi":"10.9740/mhc.2022.01.001","DOIUrl":"https://doi.org/10.9740/mhc.2022.01.001","url":null,"abstract":"Introduction: This study aims to assess the understandability, actionability, and quality of online resources for the self-management (SM) of bipolar spectrum disorders in adults.Methods: An online search using Google, Bing, and Yahoo! search engines was conducted to identify resources for bipolar disorder. Those that were published in English, discussed at least 1 method directed at improving an SM task, and were within the first 25 nonadvertisement results for each search were included. Resources directed specifically at adolescents were excluded. Understandability and actionability of the online resources were evaluated using the Patient Education Materials Assessment Tool (PEMAT). Quality of the online resources was evaluated using the DISCERN instrument. The number of SM tasks each resource discussed was also evaluated. Overall mean appropriateness was calculated by averaging the percentage scores of understandability, actionability, and quality.Results: Fifty-two resources were included. The mean sample scores were 8.4 (SD, 2.1; range, 2-13; maximum, 15) for understandability, 2.2 (SD, 1.2; range, 0-4; maximum, 5) for actionability, and 46.1 (SD, 8.9; range, 30-57; maximum, 75) for quality. The overall mean appropriateness percentage was 53.5% (SD, 11.7%; range, 18%-77%), with a goal of at least 70%. Included resources addressed a mean of 7.1 tasks (SD, 2.5; range, 1-14; maximum, 20).Discussion: Most online resources for the SM of bipolar disorder scored poorly for understandability and actionability based on PEMAT scores and had low to moderate scores for quality using the DISCERN instrument. Future online resources should be designed with the goal of increasing appropriateness for patients.","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2022-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/56/i2168-9709-12-1-1.PMC8788304.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39886276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Evaluating the impact of an emergency department protocol that guides management of methamphetamine-induced agitation and psychosis. 评估指导甲基苯丙胺引起的躁动和精神病管理的急诊科协议的影响。

The Mental Health Clinician Pub Date : 2022-01-21 eCollection Date: 2022-01-01 DOI: 10.9740/mhc.2022.01.009

Julie Nguyen, Stephen Lee, Dennis Ankrah, Erin Knox

{"title":"Evaluating the impact of an emergency department protocol that guides management of methamphetamine-induced agitation and psychosis.","authors":"Julie Nguyen, Stephen Lee, Dennis Ankrah, Erin Knox","doi":"10.9740/mhc.2022.01.009","DOIUrl":"https://doi.org/10.9740/mhc.2022.01.009","url":null,"abstract":"Background: Methamphetamine is an addictive stimulant that may induce symptoms of agitation and psychosis. The estimated rate of methamphetamine use is 6.6 per 1000 people. Currently, no treatment guidelines exist to support the optimal management of patients presenting with methamphetamine-induced agitation. Emergency department (ED) providers may prescribe various benzodiazepines (BZDs) and antipsychotics (APs) as first-line agents to stabilize these agitated patients. This study aims to determine the effectiveness of a protocol to guide management of this condition.Methods: This was a retrospective, pre- and poststudy conducted from July 2020 to March 2021 at a large academic medical center. A multidisciplinary protocol was designed to help manage methamphetamine-induced agitation in the ED. The primary outcome of the study was a reduction in the number of BZDs and APs used for the treatment of methamphetamine-induced agitation. This was measured by the incidence of overprescribing, defined as 3 or more APs or BZDs administered within 30 minutes. Secondary outcomes included the use of physical restraints, ED length of stay, and adverse events.Results: We did not observe a significantly lower incidence of overprescribing, adverse events, or ED length of stay when comparing pre- and postprotocol groups. A subgroup analysis demonstrated that when protocol was followed, there was a statistically significant reduction in overprescribing (P = .001).Discussion: We did not find any differences among our primary and secondary outcomes, which may be attributed to protocol nonadherence. Full compliance to the protocol may reduce the rate of overprescribing APs or BZDs in patients with methamphetamine-induced agitation.","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 1","pages":"9-14"},"PeriodicalIF":0.0,"publicationDate":"2022-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b5/ab/i2168-9709-12-1-9.PMC8788303.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39886277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Perceptions of clinical pharmacy specialists' contributions in mental health clinical teams. 临床药学专家对心理健康临床团队贡献的看法。

The Mental Health Clinician Pub Date : 2022-01-21 eCollection Date: 2022-01-01 DOI: 10.9740/mhc.2022.01.015

Chris Gillespie, Felicia Kleinberg, Anna Zogas, Anthony Morreale, Heather Ourth, Michael Tran, Tera Moore, Donald Miller, Megan McCullough

{"title":"Perceptions of clinical pharmacy specialists' contributions in mental health clinical teams.","authors":"Chris Gillespie, Felicia Kleinberg, Anna Zogas, Anthony Morreale, Heather Ourth, Michael Tran, Tera Moore, Donald Miller, Megan McCullough","doi":"10.9740/mhc.2022.01.015","DOIUrl":"https://doi.org/10.9740/mhc.2022.01.015","url":null,"abstract":"Introduction: Mental health (MH) clinical pharmacy specialists (CPS) are increasingly functioning as integral providers in MH care teams. MH providers may delegate many medication management tasks to the CPS. As there is a shortage of primary care and specialist MH providers, CPS are increasingly being utilized in MH care clinics. We assess provider and CPS perceptions of the contributions of CPS to MH clinical teams in the Veterans Health Administration.Methods: We examined the roles and functions of CPS in MH clinics through surveys (n = 374) and semistructured interviews (n = 16) with MH CPS and other members of MH clinical teams (psychiatrists, nurse practitioners, registered nurses, social workers) to gain insight into how CPS were integrated in these settings. We assessed perceptions of CPS contributions to MH teams, interactions between CPS and other providers, and challenges of integrating CPS into MH clinical teams.Results: Contributions of CPS in MH were received positively by clinical team members. Clinical pharmacy specialists providing comprehensive medication management were especially valuable in the management of clozapine. The knowledge and training of CPS reassured providers who frequently referred to them with questions about medication and medication therapy management. MH CPS were also perceived to be received well by patients.Discussion: The integration of MH CPS into MH teams was well received by team members and patients alike. The MH CPS have become important members of the MH team and are widely viewed as being able to improve access, quality, and workflow.","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 1","pages":"15-22"},"PeriodicalIF":0.0,"publicationDate":"2022-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/95/4e/i2168-9709-12-1-15.PMC8788298.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39886278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

A case report and literature review of olanzapine-associated hyperglycemia with previous history of gestational diabetes. 妊娠糖尿病史伴奥氮平相关高血糖1例报告及文献复习。

The Mental Health Clinician Pub Date : 2022-01-21 eCollection Date: 2022-01-01 DOI: 10.9740/mhc.2022.01.037

Jennifer N Alastanos, Devika Suri, Hayato DeLellis, Andrea Mapugay

{"title":"A case report and literature review of olanzapine-associated hyperglycemia with previous history of gestational diabetes.","authors":"Jennifer N Alastanos, Devika Suri, Hayato DeLellis, Andrea Mapugay","doi":"10.9740/mhc.2022.01.037","DOIUrl":"https://doi.org/10.9740/mhc.2022.01.037","url":null,"abstract":"Background: Olanzapine (Zyprexa) package labeling includes a warning for hyperglycemia, stating physicians should consider the risks and benefits when prescribing olanzapine to patients with an established diagnosis of diabetes mellitus or having borderline increased blood glucose levels. A case report of olanzapine-associated hyperglycemia in a patient with a history of gestational diabetes mellitus (GDM) is presented and literature review is discussed.Case report: A 33-year-old female with a past medical history of bipolar disorder, cocaine and amphetamine use disorder, hypertension, and GDM was initiated on olanzapine 5 mg PO daily which was subsequently titrated to 25 mg daily. On day 15 of admission, she developed signs and symptoms of hyperglycemia, with blood glucose readings >500 mg/dL. Insulin was initiated, olanzapine was discontinued, and her blood glucose began improving. She was later discharged on ziprasidone 20 mg PO twice daily.Discussion: There have been several case reports published on olanzapine-induced hyperglycemia. This is the first case report to specifically recognize a history of GDM as a potential risk factor for developing olanzapine-associated hyperglycemia.Conclusion: Adverse effect profiles and patient-specific risk factors should be considered when selecting appropriate antipsychotic treatment. Olanzapine may not be an ideal medication choice for a person with a history of GDM; however, if olanzapine is indicated, then close blood glucose monitoring is recommended.","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 1","pages":"37-44"},"PeriodicalIF":0.0,"publicationDate":"2022-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/00/72/i2168-9709-12-1-37.PMC8788302.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39886281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Istradefylline: A novel agent in the treatment of "off" episodes associated with levodopa/carbidopa use in Parkinson disease. iststradefylline:一种治疗帕金森病患者左旋多巴/卡比多巴相关的“off”发作的新药物。

The Mental Health Clinician Pub Date : 2022-01-21 eCollection Date: 2022-01-01 DOI: 10.9740/mhc.2022.01.032

Lauren Cummins, Marshall E Cates

{"title":"Istradefylline: A novel agent in the treatment of \"off\" episodes associated with levodopa/carbidopa use in Parkinson disease.","authors":"Lauren Cummins, Marshall E Cates","doi":"10.9740/mhc.2022.01.032","DOIUrl":"https://doi.org/10.9740/mhc.2022.01.032","url":null,"abstract":"The current gold standard for treatment of Parkinson disease (PD) is levodopa/carbidopa (L/C), but long-term treatment frequently results in motor complications, such as wearing-off and motor fluctuations (eg, dyskinesia, \"on-off\" phenomenon). Istradefylline is a new drug with a unique pharmacologic profile that was approved by the FDA for use as adjunctive treatment to L/C in adult patients with PD experiencing \"off\" episodes. The drug was shown to reduce \"off\" time in 4 randomized, double-blind, placebo-controlled studies. The most common adverse effects are dyskinesia, dizziness, constipation, nausea, hallucinations, and insomnia. Unlike many drugs that treat PD, istradefylline is a nondopaminergic drug that exerts its effects via adenosine A2A receptor antagonism. The major drug interactions involve inhibitors or inducers of CYP3A4 as well as tobacco smoking via induction of CYP1A1. Istradefylline is taken once daily as a 20- or 40-mg dose, except in cases involving drug interactions or hepatic impairment. The cost of the drug is relatively expensive, which has implications for Medicare and private insurance coverage. Istradefylline is an alternative option to dopaminergic drugs such as dopamine agonists, monoamine oxidase B inhibitors, and catechol-O-methyltransferase inhibitors as an adjunct to L/C in patients with motor fluctuations, but clinical use will further define its role in treatment of PD.","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 1","pages":"32-36"},"PeriodicalIF":0.0,"publicationDate":"2022-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/5a/i2168-9709-12-1-32.PMC8788305.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39886280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Fluctuation between cigarette smoking and use of electronic nicotine delivery systems: Impact on clozapine concentrations and clinical effect. 吸烟和电子尼古丁输送系统使用之间的波动：对氯氮平浓度和临床效果的影响。

The Mental Health Clinician Pub Date : 2021-11-08 eCollection Date: 2021-11-01 DOI: 10.9740/mhc.2021.11.365

Daniel J Montville, Jaclyn M Lindsey, Jonathan G Leung

{"title":"Fluctuation between cigarette smoking and use of electronic nicotine delivery systems: Impact on clozapine concentrations and clinical effect.","authors":"Daniel J Montville, Jaclyn M Lindsey, Jonathan G Leung","doi":"10.9740/mhc.2021.11.365","DOIUrl":"https://doi.org/10.9740/mhc.2021.11.365","url":null,"abstract":"Unlike with smoking cigarettes, electronic nicotine delivery systems do not cause CYP450 1A2 induction as there is a lack of combustion and polycyclic aromatic hydrocarbon production. Changing to the use of an electronic nicotine delivery system from cigarettes can result in the deinduction of CYP450 1A2 and the increase of certain medication serum concentrations, including clozapine. A case is reported in which the switch from smoking to an electronic nicotine delivery system resulted in increased clozapine serum concentration and constipation, necessitating pharmacologic management. The patient ultimately transitioned back to cigarettes, which resulted in the emergence of psychiatric symptoms. An evaluation of longitudinal serum concentrations and clinical correlation is provided. It is important that patients and health care professionals have knowledge not only about the impact of smoking cigarettes on clozapine metabolism, but also the effects of switching to or from an electronic nicotine delivery system.","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"11 6","pages":"365-368"},"PeriodicalIF":0.0,"publicationDate":"2021-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/29/76/i2168-9709-11-6-365.PMC8582765.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39772573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome. 抗精神病药诱导代谢综合征的临床监测与治疗要点。

The Mental Health Clinician Pub Date : 2021-11-08 eCollection Date: 2021-11-01 DOI: 10.9740/mhc.2021.11.311

Beth M DeJongh

引用次数: 5

Long-term use of antidepressants, mood stabilizers, and antipsychotics in pediatric patients with a focus on appropriate deprescribing. 儿童患者长期使用抗抑郁药、情绪稳定剂和抗精神病药物，重点是适当的处方。

The Mental Health Clinician Pub Date : 2021-11-08 eCollection Date: 2021-11-01 DOI: 10.9740/mhc.2021.11.320

Danielle L Stutzman

{"title":"Long-term use of antidepressants, mood stabilizers, and antipsychotics in pediatric patients with a focus on appropriate deprescribing.","authors":"Danielle L Stutzman","doi":"10.9740/mhc.2021.11.320","DOIUrl":"https://doi.org/10.9740/mhc.2021.11.320","url":null,"abstract":"It is estimated that 8% to 12% of youth are prescribed psychotropic medications. Those in foster care, juvenile justice systems, residential treatment facilities, and with developmental or intellectual disabilities are more likely to be prescribed high-risk regimens. The use of psychotropic medications in this age group is often off-label and can be associated with significant risk, warranting critical evaluation of their role. Landmark trials, pediatric-specific guidelines, and state-driven initiatives play critical roles in supporting evidence-based use of psychotropic medications in children. Overall, there is a lack of literature describing the long-term use of psychotropic medications in youth-particularly with regard to neurobiological, physical, and social changes that occur throughout development. Deprescribing is an important practice in child and adolescent psychiatry, given concerns for over-prescribing, inappropriate polytherapy, and the importance of reevaluating the role of psychotropic medications as children develop.","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"11 6","pages":"320-333"},"PeriodicalIF":0.0,"publicationDate":"2021-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/52/dd/i2168-9709-11-6-320.PMC8582767.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39927551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Transcranial magnetic stimulation-associated mania with psychosis: A case report. 经颅磁刺激相关躁狂症伴精神病1例。

The Mental Health Clinician Pub Date : 2021-11-08 eCollection Date: 2021-11-01 DOI: 10.9740/mhc.2021.11.373

Erin D Knox, Robert G Bota

引用次数: 1

Factors influencing performance on the Board Certified Psychiatric Pharmacist Examination: Passing rates and domain-level scores. 影响委员会精神科注册药剂师考试成绩的因素:通过率和领域水平分数。

The Mental Health Clinician Pub Date : 2021-11-08 eCollection Date: 2021-11-01 DOI: 10.9740/mhc.2021.11.358

Timothy J Muckle, Julie Dopheide, Kelly Gable, Yu Meng, Samuel G Johnson, William Ellis

{"title":"Factors influencing performance on the Board Certified Psychiatric Pharmacist Examination: Passing rates and domain-level scores.","authors":"Timothy J Muckle, Julie Dopheide, Kelly Gable, Yu Meng, Samuel G Johnson, William Ellis","doi":"10.9740/mhc.2021.11.358","DOIUrl":"https://doi.org/10.9740/mhc.2021.11.358","url":null,"abstract":"The Board Certified Psychiatric Pharmacist (BCPP) specialty certification was launched by the Board of Pharmacy Specialties in 1994. Candidates for the BCPP can qualify for the examination through 3 possible pathways: practice experience (4 years) in the specialty, completion of a PGY-1 residency plus an additional 2 years of practice experience, or completion of a PGY-2 specialty residency in psychiatric pharmacy. Recent fluctuations in the passing rate raised questions as to explanatory factors. This article represents the first published comprehensive study of candidate performance on the BCPP Examination. It describes a retrospective, observational study presenting (a) statistical trends of examination passing rates for biannual cohorts over the past 5 years, as well as (b) score distributions on the 3 performance domains of the certification. Pass-rate trend analyses suggest that variation in the proportion of eligibility pathway cohorts in the respective testing samples explains some of the fluctuation in passing rates. An analysis of variance of domain-level scores, using groups defined by eligibility pathway, yielded significant differences for nearly all group comparisons. Evaluation of the effect sizes suggest that the most disparate performance was observed on the core clinical domain, Patient-Centered Care. The results of this study are consistent with previously published research and will inform the upcoming role delineation study for the Psychiatric Pharmacy Certification.","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"11 6","pages":"358-364"},"PeriodicalIF":0.0,"publicationDate":"2021-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/81/28/i2168-9709-11-6-358.PMC8582766.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39772572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0